We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

New BD Assay Speeds Discovery in Autoimmune Disorders, Immuno-Oncology, and Infectious Diseases

By LabMedica International staff writers
Posted on 22 Apr 2022
Print article
Image: BD Rhapsody TCR/BCR multiomic assay advances immunology research capabilities in multiomics (Photo courtesy of BD)
Image: BD Rhapsody TCR/BCR multiomic assay advances immunology research capabilities in multiomics (Photo courtesy of BD)

Multiomics is a rapidly developing field where researchers look at multiple types of molecules on the same cell, which can provide greater biological insights than the traditional approach of analyzing molecules in aggregate, across many cells. Becton, Dickinson and Company (BD Franklin Lakes, NJ, USA) has launched the BD Rhapsody TCR/BCR Multiomic Assay, an innovative set of reagents that enables researchers to more easily and comprehensively analyze important cells in the immune system, providing a tool to advance research in autoimmune disorders, immuno-oncology and infectious diseases.

The BD Rhapsody TCR/BCR Multiomic Assay supplies immunology researchers the specific reagents required to profile full-length T cell and B cell receptors, two of the most important cellular elements in the immune system, to better understand the adaptive immune response and enable applications such as evaluating cellular responses to new drugs. The BD Rhapsody TCR/BCR Multiomic Assay has a wide range of applications, including screening for antigen specific cells in response to infectious diseases, immune repertoire profiling of tumor infiltrating lymphocytes, and vaccine development and evaluation of efficacy. The assay is optimized to work with the company’s BD Rhapsody Single-Cell Analysis System workflow, which enables higher capture rates than currently available solutions, preserving fragile cells in the process. This first-generation kit is now available globally and is the latest addition to BD’s portfolio of tools for multiomic analysis.

“With the release of the BD Rhapsody TCR/BCR Multiomic Assay, we are reinforcing our commitment to the incredibly exciting field of multiomics and single-cell research and the delivery of robust, easy-to-use tools that offer researchers valuable and deep insights,” said Puneet Sarin, worldwide president at BD Biosciences. “Single-cell analysis tools like the BD Rhapsody TCR/BCR Multiomic Assay and BD Rhapsody Single-Cell Analysis System support our customers’ need for greater sensitivity and specificity studying cells of interest and drive rapid advancements in immunology, including research in therapeutic response and cell therapy.”

Related Links:
Becton, Dickinson and Company 

Gold Supplier
SARS-CoV-2 IgG Antibodies Anti-S1 Assay
iRapid SARS-CoV-2 Quant "Neutralizing" Ab
Silver Supplier
Anti-Müllerian Hormone (AMH) ELISA Test
3-DIFF Hematology Analyzer

Print article


Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more


view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more


view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.